


In re Application of: Anar Palani et al.
 Serial No.: 09/995,949
 Filed: 11/28/2001

Presently Pending Claims

(Amendments highlighted in bold, language to be added underlined, language to be deleted ~~stricken through~~.)

1. (Amended) A compound of the formula:



or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

Ar¹ is aryl;

Ar² is aryl;


Ar³ is arylene;

said Ar¹, Ar² and Ar³ groups possessing ~~possesses~~ 0 to 3 substituents independently selected from the group consisting of -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, halo, -CN, -(C₁-C₆)alkoxy, -CF₃, -OCF₃, -CONH₂, -CONH(C₁-C₆)alkyl, -CON(C₁-C₆)alkyl, -NH₂, -NHC(O)(C₁-C₆)alkyl, -NHSO₂(C₁-C₆)alkyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -SO₂(C₁-C₆)alkyl, methylenedioxy and NO₂;


X is O;

Y is a single bond or a -(C₁-C₄)alkylene- group;

R¹ is



In re Application of: Anan Palani et al.
 Serial No.: 09/995,949
 Filed: 11/28/2001



R^2 is H or $-(C_1-C_6)$ alkyl;

R^3 is independently H, or nonsubstituted or halosubstituted $-(C_1-C_6)$ alkyl, $-(C_3-C_7)$ cycloalkyl, $-(C_3-C_7)$ cycloalkyl (C_1-C_6) alkyl, $-(C_1-C_6)$ alkoxy, $-(C_1-C_6)$ alkoxy (C_1-C_6) alkylene, aryl, -aralkyl or -heteroaralkyl;

R^4 is H, nonsubstituted or halosubstituted $-(C_1-C_6)$ alkyl, $-NH(C_1-C_6)$ alkyl, $-NH$ aryl, aryl; or alkoxy or hydroxy substituted alkyl, and

R^5 is independently H, or nonsubstituted or halosubstituted $-(C_1-C_6)$ alkyl, $-(C_3-C_7)$ cycloalkyl, $-(C_3-C_7)$ cycloalkyl (C_1-C_6) alkyl, aryl, -aralkyl, -heteroaralkyl, $-(C_1-C_6)$ alkoxy or (C_1-C_6) alkylene (C_1-C_6) alkoxy.

In re Application of: Anar Palani et al.
 Serial No.: 09/995,949
 Filed: 11/28/2001


2. (Previously Presented) A compound as defined in Claim 1;

or a pharmaceutically acceptable addition salt and or hydrate thereof, or
 where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar¹ and Ar² are independently phenyl or pyridyl,

Ar³ is 1, 4-arylene,

R¹ is  in which R³ is -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkylmethyl, (C₁-C₆)alkoxy- or (C₁-C₆)alkoxy(C₁-C₆)alkylene-,

R² is H,

X is O; and

Y is a single bond or -(C₁-C₃)alkylene.

3. (Canceled)

4. (Previously Presented) A compound as defined in Claim 1


or a pharmaceutically acceptable addition salt and/or hydrate thereof, or
 where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar¹ and Ar² are independently phenyl or pyridyl,

Ar³ is 1,4-arylene,

R¹ is selected from



X is O; and

In re Application of: Ana Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001

Y is $-(C_2-C_3)$ alkylene.

5. (Original) A compound as defined in Claim 2

or a pharmaceutically acceptable addition salt and/or hydrate thereof,
or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar^1 is 3-substituted phenyl or pyridyl,

Ar^2 is halo-substituted or CF_3 -substituted phenyl or pyridyl and

R^3 is methyl, ethyl, propyl, $-CH_2CH_2CF_3$, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.

6. (Original) A compound as defined in Claim 5 wherein the 3-substituent on the phenyl or pyridyl is $-CN$, $-OCF_3$ or chloro.

7. (Amended) A compound as defined in Claim ~~1~~ 3 wherein Ar^1 is 3-substituted phenyl or pyridyl, Ar^2 is halo-substituted or CF_3 -substituted phenyl or pyridyl and ~~R^5 is methyl, ethyl, propyl, $-CH_2CH_2CF_3$, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.~~


8. (Original) A compound as defined in Claim 7 wherein the 3-substituent on the phenyl or pyridyl is $-CN$, $-OCF_3$ or chloro.

9. (Amended) A compound as defined in Claim 4 wherein Ar^1 is 3-substituted phenyl or pyridyl, Ar^2 is halo-substituted or CF_3 -substituted phenyl or pyridyl and ~~R^6 is methyl, ethyl, propyl, $-CH_2CH_2CF_3$, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.~~


10. (Original) A compound as defined in Claim 9 wherein the 3-substituent on the phenyl or pyridyl is $-CN$, $-OCF_3$ or chloro.

11. (Amended) A compound as defined in Claim 1 selected from the group consisting of


In re Application of: Anam Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001




In re Application of: Anand Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001




In re Application of: Ana n Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001



In re Application of: Ana: Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001



In re Application of: A. Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001



12. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

13. (Original) A method of treating a metabolic disorder, eating disorder or diabetes in a subject in need thereof which comprises administering to said subject an effective amount of a compound as defined in claim 1.

14. (Original) A pharmaceutical composition which comprises an effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier thereof.

15. (Original) A method of treating eating disorders in a subject in need of such treatment which comprises administering to said subject a therapeutically effective amount of a compound of claim 1 or a pro-drug thereof or a pharmaceutically acceptable salt of said compound or of said pro-drug.

In re Application of: A. Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001

16. (Original) The method of claim 15 wherein said eating disorder is hyperphagia.

17. (Original) The method of claim 13 wherein said metabolic disorder is obesity.

18. (Original) A method of treating disorders associated with obesity in a subject in need of such treatment which comprises administering to said subject a therapeutically effective amount of a compound of claim 1 or a pro-drug thereof or a pharmaceutically acceptable salt of said compound or of said pro-drug.

19. (Original) The method of claim 18 wherein said disorders associated with obesity are type II diabetes, insulin resistance, hyperlipidemia and hypertension.

20. (Original) A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

a second compound, said second compound being an antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic agent or an NPY antagonist; and

a pharmaceutically acceptable carrier thereof.

21. (Original) A method of treating an eating disorder which comprises administering to a subject in need of such treatment

an amount of a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

In re Application of: A. Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001

a second compound, said second compound being an antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic agent or an NPY antagonist;

wherein the amounts of the first and second compounds result in a therapeutic effect.

22. (Original) A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, Insulin (including orally bioavailable Insulin preparations), an insulin mimetic, metformin, acarbose, a PPAR-gamma ligand such as troglitazone, rosiglitazone, pioglitazone, or GW-1929, a sulfonylurea, glipazide, glyburide, or chlorpropamide; and a pharmaceutically acceptable carrier therefor.

23. (Original) A pharmaceutical composition made by combining the compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

24. (Original) A process for making a pharmaceutical composition comprising combining a compound as defined in claim 1 and a pharmaceutically acceptable carrier.